Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
Earnings Data
Report Date
Oct 29, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.77Last Year’s EPS
-0.54Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
EyePoint announced significant progress in clinical trials and financial stability, highlighted by the rapid Phase III enrollment for DURAVYU and a strong cash position. However, the company also faced challenges with decreased revenue, increased operating expenses, and a higher net loss. The sentiment of the call reflects optimism about future milestones and the potential market position, but acknowledges the current financial strains due to increased investments in clinical trials.Company Guidance
Rapid Phase III Enrollment for DURAVYU
EyePoint successfully completed full enrollment in both Phase III LUGANO and LUCIA trials for DURAVYU in wet-AMD ahead of schedule, with over 800 patients enrolled, positioning the company for top line data in mid-2026.
Strong Financial Position
EyePoint ended Q2 2025 with $256 million in cash and investments, extending the cash runway into 2027, well beyond pivotal wet-AMD data in 2026.
Construction of cGMP Manufacturing Facility
EyePoint completed a state-of-the-art 41,000 square foot cGMP manufacturing facility in Northbridge, Massachusetts to support commercial production of DURAVYU.
Positive Phase II Results for DME
EyePoint reported highly positive results in the Phase II VERONA trial in diabetic macular edema (DME), which supports a pivotal program in this second blockbuster indication.
EYPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EYPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $10.89 | $10.58 | -2.85% |
May 07, 2025 | $6.25 | $6.09 | -2.56% |
Mar 05, 2025 | $6.08 | $6.58 | +8.22% |
Nov 07, 2024 | $12.08 | $11.59 | -4.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does EyePoint Pharmaceuticals Inc (EYPT) report earnings?
EyePoint Pharmaceuticals Inc (EYPT) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).
What is EyePoint Pharmaceuticals Inc (EYPT) earnings time?
EyePoint Pharmaceuticals Inc (EYPT) earnings time is at Oct 29, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EYPT EPS forecast?
EYPT EPS forecast for the fiscal quarter 2025 (Q3) is -0.77.